P-111 Time changes in predictive power of MDS prognostic scores – Effects on revised scores such as the IPSS-R, impact of age

Pfeilstöcker, Michael; Tüchler, Heinz; Nösslinger, Thomas; Neukirchen, Judith; Sperr, Wolfgang R.; Lübbert, Michael; Haase, D.; Stauder, R.; Krieger, O.; Valent, Peter; Germing, Ulrich

doi:10.1016/s0145-2126(13)70159-0

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the IPSS-R was shown to be an improvement over the IPSS as a classification method for predicting outcomes after standard or reduced-intensity allogeneic haematopoietic cell transplant (38). Additionally, the IWG-PM database was recently evaluated to address the potential attrition of prognostic power from the time of diagnosis, which has been a problematic issue for all prognostic scoring systems (39). Evaluating several prognostic systems, analysis showed that the IPSS-RA (IPSS-R with age normalization) retained the most prognostic power over time, followed by the IPSS-R and WPSS, which were better than the IPSS.…”

Section: Current Mds Prognostic Scoring Systems and Risk Modelsmentioning

confidence: 99%

MDS prognostic scoring systems – Past, present, and future

Jonas

Greenberg

2015

Best Practice & Research Clinical Haematology

View full text Add to dashboard Cite

The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal myeloid haemopathies characterized by defective differentiation of hematopoietic cells and expansion of the abnormal clone. This leads to the bone marrow failure with resulting peripheral blood cytopenias and evolution to or toward acute myeloid leukaemia that characterise MDS clinically. The clinical heterogeneity of MDS has led several groups to analyse patient and clinical characteristics to develop prognostic scoring systems yielding estimates of overall and leukaemia-free survival to guide clinical decision-making. These models have evolved over time as our understanding of the pathogenesis, natural history, and treatment of MDS has improved. Rapid advances in flow cytometric analysis, adjuncts to standard metaphase cytogenetics, and gene mutation analysis are revolutionizing our understanding of MDS pathogenesis and prognosis. Despite the existence of multiple well-validated prognostic scoring systems, further needed refinements of current models with these new sources of prognostic data are described.

show abstract

Section: Current Mds Prognostic Scoring Systems and Risk Modelsmentioning

confidence: 99%